Mylan Launches Generic Reclast

IV administration of zoledronic acid provides rapid and preferential distribution to areas of high bone turnover
IV administration of zoledronic acid provides rapid and preferential distribution to areas of high bone turnover

Mylan have launched Zoledronic Acid Injection, the generic version of Novartis' Reclast Injection.

Reclast is indicated to treat postmenopausal osteoporosis; to reduce the incidence of new clinical fractures in patients at high risk of fractures (those with recent low–trauma hip fracture); and for the prevention of osteoporosis in postmenopausal women. Reclast is also indicated to increase bone mass in men with osteoporosis; for the treatment of Paget's disease of bone (men and women); and for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to be on glucocorticoids for at least 12 months. 

Related Articles

Zoledronic acid, a bisphosphonate, works primarily on the bone. It is an inhibitor of osteoclast-mediated bone resorption. Intravenous administration of zoledronic acid provides rapid and preferential distribution to areas of high bone turnover. Common adverse events associated with zoledronic acid include flu-like illness and gastrointestinal symptoms.

Mylan's Zoledronic Acid Injection is available as in 5mg/100mL single-dose vials.

For more information call (800) RX-MYLAN or visit Mylan.com.